What is Kamada Ltd.'s Shariah compliance score?

Kamada Ltd. (KMDA) has a Shariah compliance score of 77/100 (Grade: B+, Good) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Kamada Ltd. pass AAOIFI screening?

Kamada Ltd. (KMDA) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (KMDA: 2.8%), (3) interest-bearing deposits below 30% (KMDA: 18.0%), and (4) prohibited income below 5% (KMDA: 1.1%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Kamada Ltd. stock?

Kamada Ltd. (KMDA) has a non-permissible income ratio of 1.06%. Muslim investors should purify this percentage of any dividends received and capital gains realized from KMDA shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Kamada Ltd. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Kamada Ltd. (KMDA) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about KMDA's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

KMDA: Is Kamada Ltd. Halal?

Kamada Ltd.

NASDAQHealthcareIL

$7.27

+1.39%

Market Cap: 419.4M

Compliance Status

Halal

Screened on Jul 15, 2026 · AAOIFI Standard 21

B+

Good

77Score

Is Kamada Ltd. (KMDA) halal? Halal. Based on AAOIFI screening, Kamada Ltd. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 77/100 (Grade: B+).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

2.8% of 30.0% limit

What this means for you

You can own KMDA

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purify 1.1% of your income from KMDA

That is about $1.10 of every $100 you earn from it. Donate this share to charity.

Calculate my exact amount

About Kamada Ltd.

Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.

Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 15, 2026

Compliance History

Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: FMP

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track KMDA and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Kamada Ltd. (KMDA) halal to invest in?

Based on AAOIFI Standard 21 screening, Kamada Ltd. (KMDA) is rated Halal with a compliance grade of B+ (Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did Kamada Ltd. get a B+ compliance rating?

Kamada Ltd. (KMDA) received a grade of B+ (Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 2.8% (limit 30%); interest-bearing deposits of 18.0% (limit 30%); prohibited income of 1.06% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Kamada Ltd.'s Shariah verdict?

Kamada Ltd.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Kamada Ltd. re-screened for Shariah compliance?

Kamada Ltd. (KMDA) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 15, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.